Major Milestone For Diurnal As FDA Approves Alkindi
Partner Eton Predicts $100m Sales For Adrenal Insufficiency Drug
Executive Summary
The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.
You may also be interested in...
Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Novartis CEO: Oncology Treatment Almost Back To Pre-COVID Levels
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.